Semaglutide Sales in 2024: What Drove the Surge?

How did semaglutide sales reach record levels in 2024?

The short answer is that clinical evidence, regulatory momentum and word of mouth all converged at once. Novo Nordisk had already published the landmark STEP 1 trial results (published in the New England Journal of Medicine, the trial showed roughly 15% average body-weight reduction over 68 weeks with 2.4mg semaglutide) and by 2024 that evidence had filtered through to GPs, patients and journalists alike. NICE had recommended Wegovy for NHS use under specific criteria. The cardiovascular data arrived too: a separate large trial showed semaglutide reduced the risk of major cardiovascular events in adults with obesity and existing heart disease, broadening the medicine's profile well beyond weight alone.

Globally, Novo Nordisk struggled to keep pace. Production facilities were expanded, but demand in the United States, Europe and the UK exceeded projections. In the UK, Wegovy sales grew faster than NHS access could accommodate, pushing a substantial portion of volume through private channels. Pharmacies operating legally under GPhC oversight saw enquiry volumes multiply. Less legitimate sellers moved in too, which is a separate and serious problem covered below.

The demand spike also reflected something simpler: people who had tried other routes for years finally had a treatment backed by robust trial data. That is a clinical reality, not a marketing event.

What was driving UK private semaglutide demand specifically?

NHS eligibility for Wegovy in 2024 was restricted to specialist weight management services under NICE technology appraisal TA875, with a maximum treatment duration of two years and BMI thresholds that left many people outside the criteria. Waiting lists for those specialist services stretched into years in some regions, and patients looking into semaglutide in Wales faced their own distinct access picture, shaped by devolved NHS commissioning decisions that differed from England's rollout. Private prescribing filled that gap — legally and appropriately for people who met the licensed eligibility criteria (BMI 30 or above, or 27 or above with a weight-related health condition) but could not access NHS provision.

The cost of private treatment rose as demand climbed. If you want to understand how pricing moved through this period, our Wegovy price comparison page sets out what private treatment typically costs and what the price should include. The short version: any legitimate price covers a full clinical assessment and prescription. A suspiciously low figure without those components is a red flag worth taking seriously.

Supply at specific doses was patchy at points during 2024. Some patients found their titration stalled while waiting for their current dose to come back into stock. That practical reality shaped purchasing decisions, and led some people toward unregulated sellers, which brings its own risks.

Did the counterfeit market grow alongside legitimate semaglutide sales?

Yes, and the MHRA has been explicit about this. As legitimate GLP-1 use rose, counterfeit pens multiplied online and via social media. The MHRA's enforcement activity through 2024 and into 2025 uncovered large volumes of fake pens (some containing insulin rather than semaglutide) and issued repeated public warnings. In October 2025 alone, enforcement actions included the raid of a manufacturing site producing counterfeit tirzepatide pens. The 2024 growth in semaglutide sales cannot be separated from the parallel growth in the illicit market.

For anyone purchasing semaglutide privately, the verification step is simple and takes about 30 seconds: check any online pharmacy on the GPhC register at pharmacyregulation.org/registers. A pharmacy that cannot be found there should not be dispensing prescription medicines. Sellers offering Wegovy without requiring a prescription, at prices far below the legitimate market, or through social media direct messages are operating outside UK law.

Think of it this way: the pen sitting in the fridge door between the milk and the orange juice needs to be exactly what the label says it is. With a counterfeit, there is no way to know.

What do the 2024 numbers suggest about where semaglutide goes next?

The 2024 sales figures for semaglutide set a baseline that 2025 and beyond have continued to build on. For context on how that trajectory continued, Wegovy sales in 2025 reflected further regulatory developments, including the MHRA's approval of a 7.2mg maintenance dose, a higher dose than was available through most of 2024, reporting roughly 20.7% average weight loss in trials. Oral semaglutide (Wegovy tablets) gained UK approval in June 2026, opening the medicine to people who cannot or prefer not to inject. The revenue picture for 2024 specifically reflects the injection-only era, before oral GLP-1 weight-management treatment existed in the UK at all.

In parallel, tirzepatide (Mounjaro) entered the UK weight-management market through 2023 and gained pace through 2024, with NICE recommending it in December of that year. The SURMOUNT-5 trial, published in 2025, showed tirzepatide produced greater average weight loss than semaglutide 2.4mg in a direct comparison. That competitive dynamic will continue to shape how semaglutide is positioned in the UK market. What it means for patients, though, is a genuine clinical choice rather than a default, and that choice belongs to a prescriber who knows the individual's full picture, not a sales chart. You can explore the broader treatment landscape on our weight loss overview, and when you're ready, speak to our prescribers about what suits you specifically.